Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 89

1.

Corrigendum: Designer Leptin Receptor Antagonist Allo-aca Inhibits VEGF Effects in Ophthalmic Neoangiogenesis Models.

Coroniti R, Farjo R, Nuno DJ, Otvos L, Scolaro L, Surmacz E.

Front Mol Biosci. 2016 Nov 18;3:75. eCollection 2016.

2.

Designer Leptin Receptor Antagonist Allo-aca Inhibits VEGF Effects in Ophthalmic Neoangiogenesis Models.

Coroniti R, Fario R, Nuno DJ, Otvos L, Scolaro L, Surmacz E.

Front Mol Biosci. 2016 Oct 13;3:67. eCollection 2016. Erratum in: Front Mol Biosci. 2016 Nov 18;3:75.

3.

Molecular targeting of obesity pathways in cancer.

Surmacz E, Otvos L.

Horm Mol Biol Clin Investig. 2015 May;22(2):53-62. doi: 10.1515/hmbci-2015-0007. Review.

PMID:
25879324
4.

Optimization of adiponectin-derived peptides for inhibition of cancer cell growth and signaling.

Otvos L Jr, Kovalszky I, Olah J, Coroniti R, Knappe D, Nollmann FI, Hoffmann R, Wade JD, Lovas S, Surmacz E.

Biopolymers. 2015 May;104(3):156-66. doi: 10.1002/bip.22627.

PMID:
25683126
5.

Development of second generation peptides modulating cellular adiponectin receptor responses.

Otvos L Jr, Knappe D, Hoffmann R, Kovalszky I, Olah J, Hewitson TD, Stawikowska R, Stawikowski M, Cudic P, Lin F, Wade JD, Surmacz E, Lovas S.

Front Chem. 2014 Oct 17;2:93. doi: 10.3389/fchem.2014.00093. eCollection 2014.

6.

Designer adiponectin receptor agonist stabilizes metabolic function and prevents brain injury caused by HIV protease inhibitors.

Pepping JK, Otvos L Jr, Surmacz E, Gupta S, Keller JN, Bruce-Keller AJ.

J Neuroimmune Pharmacol. 2014 Jun;9(3):388-98. doi: 10.1007/s11481-014-9529-1. Epub 2014 Feb 23.

7.

The designer leptin antagonist peptide Allo-aca compensates for short serum half-life with very tight binding to the receptor.

Otvos L Jr, Vetter SW, Koladia M, Knappe D, Schmidt R, Ostorhazi E, Kovalszky I, Bionda N, Cudic P, Surmacz E, Wade JD, Hoffmann R.

Amino Acids. 2014 Apr;46(4):873-82. doi: 10.1007/s00726-013-1650-6. Epub 2013 Dec 24.

PMID:
24366600
8.

Leptin and adiponectin: emerging therapeutic targets in breast cancer.

Surmacz E.

J Mammary Gland Biol Neoplasia. 2013 Dec;18(3-4):321-32. doi: 10.1007/s10911-013-9302-8. Epub 2013 Oct 18. Review.

PMID:
24136336
9.

Exploring leptin antagonism in ophthalmic cell models.

Scolaro L, Parrino C, Coroniti R, Otvos L Jr, Surmacz E.

PLoS One. 2013 Oct 3;8(10):e76437. doi: 10.1371/journal.pone.0076437. eCollection 2013.

10.

Designer peptide antagonist of the leptin receptor with peripheral antineoplastic activity.

Beccari S, Kovalszky I, Wade JD, Otvos L Jr, Surmacz E.

Peptides. 2013 Jun;44:127-34. doi: 10.1016/j.peptides.2013.03.027. Epub 2013 Apr 6.

PMID:
23567149
11.

Effects of PPARĪ³ agonists on the expression of leptin and vascular endothelial growth factor in breast cancer cells.

Terrasi M, Bazan V, Caruso S, Insalaco L, Amodeo V, Fanale D, Corsini LR, Contaldo C, Mercanti A, Fiorio E, Lo Re G, Cicero G, Surmacz E, Russo A.

J Cell Physiol. 2013 Jun;228(6):1368-74. doi: 10.1002/jcp.24295.

PMID:
23254958
12.

Metformin inhibits leptin-induced growth and migration of glioblastoma cells.

Ferla R, Haspinger E, Surmacz E.

Oncol Lett. 2012 Nov;4(5):1077-1081. Epub 2012 Aug 3.

13.

Design and development of a peptide-based adiponectin receptor agonist for cancer treatment.

Otvos L Jr, Haspinger E, La Russa F, Maspero F, Graziano P, Kovalszky I, Lovas S, Nama K, Hoffmann R, Knappe D, Cassone M, Wade J, Surmacz E.

BMC Biotechnol. 2011 Oct 5;11:90. doi: 10.1186/1472-6750-11-90.

14.

Targeting the leptin receptor: a potential new mode of treatment for breast cancer.

Otvos L Jr, Surmacz E.

Expert Rev Anticancer Ther. 2011 Aug;11(8):1147-50. doi: 10.1586/era.11.109. No abstract available.

PMID:
21916566
15.

Glioblastoma-derived leptin induces tube formation and growth of endothelial cells: comparison with VEGF effects.

Ferla R, Bonomi M, Otvos L Jr, Surmacz E.

BMC Cancer. 2011 Jul 19;11:303. doi: 10.1186/1471-2407-11-303.

16.

Toward understanding the role of leptin and leptin receptor antagonism in preclinical models of rheumatoid arthritis.

Otvos L Jr, Shao WH, Vanniasinghe AS, Amon MA, Holub MC, Kovalszky I, Wade JD, Doll M, Cohen PL, Manolios N, Surmacz E.

Peptides. 2011 Aug;32(8):1567-74. doi: 10.1016/j.peptides.2011.06.015. Epub 2011 Jun 23.

PMID:
21723351
17.

Efficacy of a leptin receptor antagonist peptide in a mouse model of triple-negative breast cancer.

Otvos L Jr, Kovalszky I, Riolfi M, Ferla R, Olah J, Sztodola A, Nama K, Molino A, Piubello Q, Wade JD, Surmacz E.

Eur J Cancer. 2011 Jul;47(10):1578-84. doi: 10.1016/j.ejca.2011.01.018. Epub 2011 Feb 23.

PMID:
21353530
18.

Obesity hormone leptin induces growth and interferes with the cytotoxic effects of 5-fluorouracil in colorectal tumor stem cells.

Bartucci M, Svensson S, Ricci-Vitiani L, Dattilo R, Biffoni M, Signore M, Ferla R, De Maria R, Surmacz E.

Endocr Relat Cancer. 2010 Aug 16;17(3):823-33. doi: 10.1677/ERC-10-0083. Print 2010 Sep.

PMID:
20603394
19.

Relationships between hypoxia markers and the leptin system, estrogen receptors in human primary and metastatic breast cancer: effects of preoperative chemotherapy.

Koda M, Kanczuga-Koda L, Sulkowska M, Surmacz E, Sulkowski S.

BMC Cancer. 2010 Jun 22;10:320. doi: 10.1186/1471-2407-10-320.

20.

Peptide-based leptin receptor antagonists for cancer treatment and appetite regulation.

Otvos L Jr, Kovalszky I, Scolaro L, Sztodola A, Olah J, Cassone M, Knappe D, Hoffmann R, Lovas S, Hatfield MP, Beko G, Zhang S, Wade JD, Surmacz E.

Biopolymers. 2011;96(2):117-25. doi: 10.1002/bip.21377.

PMID:
20564005

Supplemental Content

Loading ...
Support Center